Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 14, 2022 08:47 ET | Source: Genmab A/S

Genmab Announces the Nomination of a New Member of the Company’s Board of Directors

Company Announcement Genmab’s Board of Directors proposes that Elizabeth O’Farrell is elected as a new member of the Board of Directors COPENHAGEN, Denmark; March 14, 2022 – Genmab A/S (Nasdaq:...
March 08, 2022 07:31 ET | Source: Genmab A/S

Genmab Announces U.S. Food and Drug Administration Granted Orphan-Drug Designation to Epcoritamab (DuoBody®-CD3xCD20) in Follicular Lymphoma

Media Release COPENHAGEN, Denmark; March 8, 2022 Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to the investigational...
March 01, 2022 09:14 ET | Source: Genmab A/S

Genmab Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer

Media Release COPENHAGEN, Denmark; March 1, 2022Genmab A/S (Nasdaq: GMAB) announced today that Birgitte Stephensen has been appointed to Chief Legal Officer and Chris Cozic has been appointed to...
February 25, 2022 16:19 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; February 25, 2022 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...
February 25, 2022 16:13 ET | Source: Genmab A/S

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; February 25, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that the board decided to grant 190,202 restricted stock units to five members of management...
February 24, 2022 10:00 ET | Source: Genmab A/S

Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma

Media ReleaseCOPENHAGEN, Denmark, and BOTHELL, Wash., February 24, 2022 Data from the innovaTV 207 global phase 2 trial to be presented at the American Society for Radiation Oncology (ASTRO) 2022...
February 24, 2022 06:01 ET | Source: Genmab A/S

Notice to Convene the Annual General Meeting of Genmab A/S

Company Announcement Genmab A/S to hold Annual General Meeting on Tuesday March 29, 2022 COPENHAGEN, Denmark; February 24, 2022 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on...
February 22, 2022 14:11 ET | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; February 22, 2022 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 15,685 shares as a consequence of the exercise of employee warrants. The...
February 16, 2022 14:14 ET | Source: Genmab A/S

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

Media ReleaseCopenhagen, Denmark, February 16, 2022 Genmab filed Form 20-F for the financial year 2021 with the U.S. SEC Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report...
February 16, 2022 11:00 ET | Source: Genmab A/S

Genmab Publishes 2021 Annual Report

Genmab Publishes 2021 Annual Report Company Announcement Copenhagen, Denmark; February 16, 2022 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2021. Below is a...